Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.

JCO precision oncology - 1 Jan 2022

Wintheiser Grant, Zemla Tyler, Shi Qian, Tran Nguyen, Prasai Kritika, Tella Sri Harsha, Mody Kabir, Ahn Daniel, Borad Mitesh, Bekaii-Saab Tanios, Mahipal Amit

Abstract excerpt

PURPOSE: Clinical-pathologic features and natural history of patients with isocitrate dehydrogenase (IDH)-mutant intrahepatic cholangiocarcinoma (CCA) are not well characterized. Here, we sought to describe the natural history, clinical phenotype, and prognostic impact of advanced, IDH-mutated CCA. METHODS: We conducted a multicentric, retrospective analysis of patients with IDH-mutated (IDH1 or IDH2) CCA between...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bile Duct Neoplasms

Share to Bile Ducts, Intrahepatic

Share to Cholangiocarcinoma

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Survival Rate

Source

Identifiers

PMID: 35005992
DOI: 10.1200/PO.21.00156

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.PMID 35005992Read ↗

Mutation Rate of IDH1 and the Impact of Pathological Features on Survival in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center.Semantic proximity Read ↗

Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.Semantic proximity Read ↗

Intrahepatic cholangiocarcinoma: current management and emerging therapies.Semantic proximity Read ↗

Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Update on cholangiocarcinoma: potential impact of genomic studies on clinical management.Semantic proximity Read ↗

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.Semantic proximity Read ↗

Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises-a narrative review.Semantic proximity Read ↗

Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.